Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suncoast Research Associates

Neither a doctor nor a teaching hospital

Research payments

$5,387,684

160 payments

Through program year 2025, Suncoast Research Associates is reported as receiving $5,387,684 in research payments, across 160 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,347,996 40
2024 Research $322,230 31
2023 Research $2,256,420 58
2022 Research $81,947 7
2021 Research $1,231,080 15
2020 Research $147,941 8
2019 Research $70 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $1,898,171 97 payments
  2. Vertex Pharmaceuticals Incorporated $1,404,677 7 payments
  3. Valneva Austria GmbH $1,344,862 17 payments
  4. Merck Sharp & Dohme Corporation $378,808 5 payments
  5. GlaxoSmithKline, LLC. $305,012 20 payments
  6. Genentech, Inc. $24,888 4 payments
  7. AstraZeneca Pharmaceuticals LP $17,700 2 payments
  8. Sanofi Pasteur Inc. $9,200 1 payment
  9. Pfizer Inc. $3,995 5 payments
  10. Moderna TX, Inc. $371 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $1,637,632 45 payments
  2. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $1,344,862 17 payments
  3. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $655,214 2 payments
  4. A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $388,159 2 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $347,134 4 payments
  6. A Phase 1, Single-Blind, Safety, Reactogenicity, and Immunogenicity Tr $254,853 17 payments
  7. Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $204,539 2 payments
  8. A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $156,765 1 payment
  9. Ebsi-Cv-317-008 $138,574 33 payments
  10. Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination $119,564 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record